{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T16:26:24Z","timestamp":1747412784253},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T00:00:00Z","timestamp":1199318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00296-007-0503-6","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T09:08:42Z","timestamp":1199264922000},"page":"661-665","source":"Crossref","is-referenced-by-count":5,"title":["Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-\u03b22-glycoprotein-I autoantibodies"],"prefix":"10.1007","volume":"28","author":[{"given":"Anjana","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Illges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,3]]},"reference":[{"issue":"10","key":"503_CR1","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.4049\/jimmunol.143.10.3200","volume":"143","author":"W Timens","year":"1989","unstructured":"Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S (1989) Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143(10):3200\u20133206","journal-title":"J Immunol"},{"issue":"6386","key":"503_CR2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/358505a0","volume":"358","author":"JP Aubry","year":"1992","unstructured":"Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY (1992) CD21 is a ligand for CD23 and regulates IgE production. Nature 358(6386):505\u2013507","journal-title":"Nature"},{"issue":"9","key":"503_CR3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/eji.200323843","volume":"33","author":"M Masilamani","year":"2003","unstructured":"Masilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H (2003) B cell activation leads to shedding of complement receptor type II (CR2\/CD21). Eur J Immunol 33(9):2391\u20132397","journal-title":"Eur J Immunol"},{"issue":"5","key":"503_CR4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1078\/0171-2985-00201","volume":"206","author":"M Masilamani","year":"2002","unstructured":"Masilamani M, von Seydlitz E, Bastmeyer M, Illges H (2002) T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein\u2013Barr virus\/C3d receptor (CR2\/CD21) gene and protein expression. Immunobiology 206(5):528\u2013536","journal-title":"Immunobiology"},{"issue":"1","key":"503_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2249.1991.tb08117.x","volume":"84","author":"N Ling","year":"1991","unstructured":"Ling N, Hansel T, Richardson P, Brown B (1991) Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia. Clin Exp Immunol 84(1):16\u201322","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"503_CR6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000463012","volume":"4","author":"BL Myones","year":"1987","unstructured":"Myones BL, Ross GD (1987) Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement 4(2):87\u201398","journal-title":"Complement"},{"issue":"3","key":"503_CR7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1073\/pnas.81.3.881","volume":"81","author":"JJ Weis","year":"1984","unstructured":"Weis JJ, Tedder TF, Fearon DT (1984) Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci USA 81(3):881\u2013885","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"503_CR8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2249.1993.tb07965.x","volume":"93","author":"HP Huemer","year":"1993","unstructured":"Huemer HP, Larcher C, Prodinger WM, Petzer AL, Mitterer M, Falser N (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin Exp Immunol 93(2):195\u2013199","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"503_CR9","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.4049\/jimmunol.135.4.2687","volume":"135","author":"M Reynes","year":"1985","unstructured":"Reynes M, Aubert JP, Cohen JH, Audouin J, Tricottet V, Diebold J, Kazatchkine MD (1985) Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 135(4):2687\u20132694","journal-title":"J Immunol"},{"issue":"8","key":"503_CR10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/eji.1830180823","volume":"18","author":"CD Tsoukas","year":"1988","unstructured":"Tsoukas CD, Lambris JD (1988) Expression of CR2\/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol 18(8):1299\u20131302","journal-title":"Eur J Immunol"},{"issue":"5028","key":"503_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1718035","volume":"254","author":"T Hebell","year":"1991","unstructured":"Hebell T, Ahearn JM, Fearon DT (1991) Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254(5028):102\u2013105","journal-title":"Science"},{"issue":"9","key":"503_CR12","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.4049\/jimmunol.161.9.4549","volume":"161","author":"D Qin","year":"1998","unstructured":"Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG (1998) Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 161(9):4549\u20134554","journal-title":"J Immunol"},{"issue":"3","key":"503_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4049\/jimmunol.146.3.865","volume":"146","author":"E Fischer","year":"1991","unstructured":"Fischer E, Delibrias C, Kazatchkine MD (1991) Expression of CR2 (the C3dg\/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol 146(3):865\u2013869","journal-title":"J Immunol"},{"issue":"14","key":"503_CR14","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","volume":"81","author":"JD Fingeroth","year":"1984","unstructured":"Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT (1984) Epstein\u2013Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81(14):4510\u20134514","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"503_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-2478(89)90093-X","volume":"20","author":"J Lowe","year":"1989","unstructured":"Lowe J, Brown B, Hardie D, Richardson P, Ling N (1989) Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia. Immunol Lett 20(2):103\u2013109","journal-title":"Immunol Lett"},{"issue":"3","key":"503_CR16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.149.3.768","volume":"149","author":"CC Delibrias","year":"1992","unstructured":"Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD (1992) Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol 149(3):768\u2013774","journal-title":"J Immunol"},{"issue":"34","key":"503_CR17","doi-asserted-by":"crossref","first-page":"20576","DOI":"10.1016\/S0021-9258(19)47101-9","volume":"264","author":"MD Moore","year":"1989","unstructured":"Moore MD, DiScipio RG, Cooper NR, Nemerow GR (1989) Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein\u2013Barr virus\/C3dg receptor (CR2). J Biol Chem 264(34):20576\u201320582","journal-title":"J Biol Chem"},{"issue":"6","key":"503_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.0300-9475.2004.01494.x","volume":"60","author":"M Masilamani","year":"2004","unstructured":"Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of soluble complement receptor 2\/CD21 in systemic lupus erythomatosus and Sjogren\u2019s syndrome but not juvenile arthritis. Scand J Immunol 60(6):625\u2013630","journal-title":"Scand J Immunol"},{"issue":"10","key":"503_CR19","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/intimm\/10.10.1459","volume":"10","author":"V Fremeaux-Bacchi","year":"1998","unstructured":"Fremeaux-Bacchi V, Fischer E, Lecoanet-Henchoz S, Mani JC, Bonnefoy JY, Kazatchkine MD (1998) Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. Int Immunol 10(10):1459\u20131466","journal-title":"Int Immunol"},{"issue":"12","key":"503_CR20","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.4049\/jimmunol.168.12.6279","volume":"168","author":"D Ulgiati","year":"2002","unstructured":"Ulgiati D, Pham C, Holers VM (2002) Functional analysis of the human complement receptor 2 (CR2\/CD21) promoter: characterization of basal transcriptional mechanisms. J Immunol 168(12):6279\u20136285","journal-title":"J Immunol"},{"issue":"Pt 6","key":"503_CR21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1042\/bst0300983","volume":"30","author":"J Hannan","year":"2002","unstructured":"Hannan J, Young K, Szakonyi G, Overduin MJ, Perkins SJ, Chen X, Holers VM (2002) Structure of complement receptor (CR) 2 and CR2-C3d complexes. Biochem Soc Trans 30(Pt 6):983\u2013989","journal-title":"Biochem Soc Trans"},{"issue":"8705","key":"503_CR22","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0140-6736(90)91374-J","volume":"335","author":"M Galli","year":"1990","unstructured":"Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335(8705):1544\u20131547","journal-title":"Lancet"},{"key":"503_CR23","doi-asserted-by":"crossref","unstructured":"Masilamani M, von Kempis J, Illges H (2004) Decreased levels of serum soluble complement receptor-II (CR2\/CD21) in patients with rheumatoid arthritis. Rheumatology 43(2):186\u2013190","DOI":"10.1093\/rheumatology\/keg449"},{"issue":"1","key":"503_CR24","first-page":"41","volume":"12","author":"LR Sammaritano","year":"1992","unstructured":"Sammaritano LR, Gharavi AE (1992) Antiphospholipid antibody syndrome. Clin Lab Med 12(1):41\u201359","journal-title":"Clin Lab Med"},{"issue":"7","key":"503_CR25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1191\/0961203303lu396xx","volume":"12","author":"Y Shoenfeld","year":"2003","unstructured":"Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12(7):497\u2013498","journal-title":"Lupus"},{"issue":"1","key":"503_CR26","first-page":"100","volume":"21","author":"M Blank","year":"1994","unstructured":"Blank M, Tincani A, Shoenfeld Y (1994) Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 21(1):100\u2013104","journal-title":"J Rheumatol"},{"issue":"9","key":"503_CR27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.97.9.900","volume":"97","author":"J George","year":"1998","unstructured":"George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A, Shoenfeld Y (1998) Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97(9):900\u2013906","journal-title":"Circulation"},{"issue":"8","key":"503_CR28","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1073\/pnas.88.8.3069","volume":"88","author":"M Blank","year":"1991","unstructured":"Blank M, Cohen J, Toder V, Shoenfeld Y (1991) Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 88(8):3069\u20133073","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"503_CR29","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1073\/pnas.96.9.5164","volume":"96","author":"M Blank","year":"1999","unstructured":"Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 96(9):5164\u20135168","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"503_CR30","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.4049\/jimmunol.161.10.5303","volume":"161","author":"M Blank","year":"1998","unstructured":"Blank M, George J, Barak V, Tincani A, Koike T, Shoenfeld Y (1998) Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. J Immunol 161(10):5303\u20135312","journal-title":"J Immunol"},{"issue":"5","key":"503_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.it.2005.03.006","volume":"26","author":"P Meroni","year":"2005","unstructured":"Meroni P, Ronda N, Raschi E, Borghi MO (2005) Humoral autoimmunity against endothelium: theory or reality? Trends Immunol 26(5):275\u2013281","journal-title":"Trends Immunol"},{"issue":"6","key":"503_CR32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1172\/JCI0212337","volume":"109","author":"M Blank","year":"2002","unstructured":"Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y (2002) Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109(6):797\u2013804","journal-title":"J Clin Invest"},{"issue":"1","key":"503_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-1759(02)00211-9","volume":"270","author":"M Masilamani","year":"2002","unstructured":"Masilamani M, Apell HJ, Illges H (2002) Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 270(1):11\u201318","journal-title":"J Immunol Methods"},{"issue":"6","key":"503_CR34","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.4049\/jimmunol.174.6.3264","volume":"174","author":"T Lyubchenko","year":"2005","unstructured":"Lyubchenko T, dal Porto J, Cambier JC, Holers VM (2005) Coligation of the B cell receptor with complement receptor type 2 (CR2\/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 174(6):3264\u20133272","journal-title":"J Immunol"},{"issue":"5522","key":"503_CR35","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1126\/science.1059118","volume":"292","author":"G Szakonyi","year":"2001","unstructured":"Szakonyi G, Guthridge JM, Li D, Young K, Holers VM, Chen XS (2001) Structure of complement receptor 2 in complex with its C3d ligand. Science 292(5522):1725\u20131728","journal-title":"Science"},{"issue":"21","key":"503_CR36","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1016\/S0021-9258(19)38344-9","volume":"265","author":"JC Carel","year":"1990","unstructured":"Carel JC, Myones BL, Frazier B, Holers VM (1990) Structural requirements for C3d, g\/Epstein\u2013Barr virus receptor (CR2\/CD21) ligand binding, internalization, and viral infection. J Biol Chem 265(21):12293\u201312299","journal-title":"J Biol Chem"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-007-0503-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0503-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:46:50Z","timestamp":1684162010000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-007-0503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,3]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s00296-007-0503-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,3]]}}}